Published in Obesity and Diabetes Week, January 24th, 2005
The license will provide J&JPRD with rights under patents covering the technologies frequently referred to as "isogenic DNA" and "positive-negative selection" to generate and use knockout mice in its internal drug discovery research. Financial terms of the agreement were not disclosed.
"J&JPRD is the 13th licensee of Lexicon's proprietary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week